Navigation Links
Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
Date:9/13/2011

LISBON, Portugal, Sept. 13, 2011 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) presented results today demonstrating its novel insulin sensitizers, MSDC-0160 and MSDC-0602, stimulate progenitor cells within subcutaneous fat tissue to become brown-like fat cells instead of white fat cells. Brown fat, which diminishes with age, burns calories while white fat stores calories. The mechanism of action by which MSDC-0160 and MSDC-0602 cause these effects is independent of the activation PPARy, a factor that drives the expansion of white fat. These findings suggest the potential for minimizing weight gain normally associated with currently marketed insulin sensitizers, and may result in weight loss in longer duration clinical studies. The data were presented in an oral presentation at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal.

MSDC-0160 and MSDC-0602 are novel insulin sensitizers that are selective for mTOT, a mitochondrial molecular target that functions as a "switch" connecting mitochondrial metabolism to important cell functions.  Previous studies have shown the PPAR-independent pharmacology of each of these compounds results in improved insulin action, preservation of beta cell function, and generation of brown fat. The amount of brown fat is inversely proportioned to body weight (and white fat).

"Given the novel mechanism of action of our compounds, we expect to see weight control over longer duration treatments with these new clinical candidates as a result of the "browning" of adipose or fat stores," said Jerry Colca, Ph.D., president and Chief Scientific Officer of MSDC. "These results in the preclinical setting have important mechanistic implications for developing future therapies and provide a framework for further defining the mTOT biochemical pathway."

Study Methodology and Key Results

In this in vitro study, progenitor cells from axillary adipose depots (fat tissue located in the armpit region) were isolated from mice and placed in tissue culture under defined conditions. Treatment of these cells with micromolar concentrations of the MSDC compounds elicited a time- and dose-dependent differentiation of the progenitor cells into brown-like adipose cells. The brown-like adipose cells express UCP1 message and protein in a process that includes increased mitochondrial biogenesis. These effects were not attenuated by the potent PPARy antagonists, T0070907 and GW9662, confirming the PPAR-independent pharmacology of the MSDC compound.  Importantly, the cells from axillary adipose depots also secreted the insulin-sensitizing hormone adiponectin in response to the MSDC compounds. These results show that novel insulin sensitizers that increase brown fat could have important implications for the development of new therapies to treat type 2 diabetes.

About Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and new therapies for metabolic diseases associated with mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised more than $55 million to support development of its lead compounds MSDC-0160 and MSDC-0602.


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolic Solutions Development Company Receives $773,000 From the Alzheimers Drug Discovery Foundation to Fund Phase 2a Trial
2. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
3. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
4. Bariatric Advantage to Attend American Society of Metabolic and Bariatric Surgery (ASMBS) Conference
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management
7. Atherotech Unveils New Cardiometabolic Test Panels
8. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
11. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech ... a leading provider of biopharmaceutical products in ... of its board of directors received on February 4, ... 2016, from a consortium comprised of PKU V-Ming ( ... Biomedicine Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading ... to the North American healthcare market. , Aerocom Healthcare, LLC will be based ... company will provide new pneumatic tube systems or expand existing systems within the ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):